HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Medulloblastoma study of the German Society for Pediatric Oncology, a first report].

Abstract
The principle of giving intensive polychemotherapy in the time between operation and irradiation was applied in a cooperative phase-2-study in children with medulloblastoma of the posterior fossa. A first evaluation of 33 of 47 registered patients was attempted after the study existing now for 1 year and 10 months. In the majority of patients the chemotherapy protocol could be fully realized without any deductions. Side effects including two therapy related fatalities were analysed. In all patients irradiation was not delayed and could be started about 11 weeks after operation and could be carried through without any major draw-backs. Analysis of survival can only be preliminary due to the short duration of the study, but patients' survival is compatible with other reported studies. The therapeutic principle presented here shall be compared in a randomized and extended fashion with a conventional therapeutic approach.
AuthorsM Neidhardt, H J Habermalz, G Henze, H J Langermann
JournalKlinische Padiatrie (Klin Padiatr) 1982 Jul-Aug Vol. 194 Issue 4 Pg. 257-61 ISSN: 0300-8630 [Print] Germany
Vernacular TitleMedulloblastomstudie der Gesellschaft für Pädiatrische Onkologie, ein Zwischenbericht.
PMID7132227 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Procarbazine
  • Vincristine
  • Methotrexate
Topics
  • Adolescent
  • Adult
  • Cerebellar Neoplasms (drug therapy, radiotherapy, surgery)
  • Child
  • Child, Preschool
  • Female
  • Germany, West
  • Humans
  • Male
  • Medulloblastoma (drug therapy, radiotherapy, surgery)
  • Methotrexate (therapeutic use)
  • Postoperative Care
  • Procarbazine (therapeutic use)
  • Radiotherapy Dosage
  • Registries
  • Vincristine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: